Brief: Irlab Reports Top Line Results From Phase Iia Study With Irl790

IRLAB Therapeutics AB

15/07/2019 23:21

July 15 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB REPORTS TOP LINE RESULTS FROM PHASE IIA STUDY WITH
IRL790
    * IRLAB THERAPEUTICS-OVERALL RESULTS IN FIRST PHASE IIA
STUDY WITH
INDICATIONS OF EFFICACY LACK OF SAFETY CONCERNS SUPPORT FURTHER
DEVELOPMENT OF IRL790
    * THERE WAS NO DIFFERENCE, IRL790 VERSUS. PLACEBO, ON
DYSKINESIAS
MEASURED WITH UDYSRS TOTAL SCORE
    * IMPROVEMENT VERSUS. PLACEBO WAS OBSERVED IN MDS-UPDRS
DYSKINESIA
RATINGS AND IN DYSKINESIAS REPORTED WITH PATIENT DIARIES
    * IRL790 WAS WELL TOLERATED IN STUDY

Source text for Eikon:  ID:nWkr1QjvKb 
Further company coverage:  IRLABa.ST 

 ((Reuters.Briefs@thomsonreuters.com;))